Announcements

Results of peptide vaccine clinical trial discussed by Hopkins team

Over the last few years, a team of investigators at Johns Hopkins University conducted an innovative clinical trial designed to test the potential to induce an immune response against fibrolamellar carcinoma with a FLC-specific therapeutic vaccine. Participants in the clinical trial were given an experimental vaccine containing a peptide (a small segment of a protein) …

Read more

New research collaboration with X-Chem

FCF is pleased to announce the establishment of a research collaboration with X-Chem, a global leader in DNA-encoded library (DEL) technology. Through the effort, X-Chem will leverage its powerful DEL platform to support drug discovery efforts against fibrolamellar’s difficult-to-drug fusion protein. The hope is that this powerful screening technology can be used to identify potential …

Read more

New Year Wishes

As we stand on the cusp of a brand new year, the Fibrolamellar Cancer Foundation extends warm wishes to the entire fibrolamellar community. May the coming year bring: FCF is committed to work collaboratively to build a brighter future for those touched by this disease. Please join us in the effort to reduce the fear …

Read more

Giving Tuesday 2023

Each year, the Tuesday after Thanksgiving celebrates giving as a way to transform the world. Giving Tuesday was created in 2012 as a day that encourages people to “do good”. Over the past 11 years, this idea has grown into a global movement that inspires hundreds of millions of people to give, collaborate, and celebrate generosity …

Read more

FCF funds new multi-institution collaboration

FCF is please to announce that it has funded a new study directed by Roshni Dasgupta, MD of the Cincinnati Children’s Hospital Medical Center (CCHMC). Dr. Dasgupta is a leader in surgical oncology and the chair of the Pediatric Surgical Oncology Research Collaborative (PSORC). PSORC includes 41 member institutions and has a mission “to improve …

Read more

New clinical trial open in Germany

This week, a new clinical trial of a peptide vaccine treated its first patient in Tübingen, Germany. The trial, named FusionVAC22_01: Fusion Transcript-based Peptide Vaccine Combined With Immune Checkpoint Inhibition is expected to enroll 20 patients with fibrolamellar carcinoma or other cancers carrying the DNAJB1-PRKACA fusion transcript. Study goals This phase I study will examine …

Read more

2024 fibrolamellar calendars

Thanks to the efforts of FCF’s Patient & Caregiver Advisory Board, we will be producing fibrolamellar calendars in 2024!

Read more

FCF funds grant continuation at University of Washington

FCF has awarded a grant for additional studies to be conducted by John Scott, PhD of the University of Washington in Seattle. As the Chair of the Department of Pharmacology, Dr. Scott has been a key leader of a multi-disciplinary team working on FLC at the University of Washington and the Fred Hutchinson Cancer Center …

Read more

Thank you to Stone Point Capital!

A heartfelt thank you goes out to Stone Point Capital, as well as the sponsors and participants in the 2023 Stone Point Capital Charity Golf Tournament. Since 2009 Stone Point Capital has dedicated the proceeds from its annual charity event to FCF.  This years event, held in Connecticut on October 2nd, raised a record amount …

Read more